Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Effect of Dehydroepiandrosterone Replacement on Insulin Sensitivity and Lipids in Hypoadrenal Women
Ist Teil von
Diabetes (New York, N.Y.), 2005-03, Vol.54 (3), p.765-769
Ort / Verlag
Alexandria, VA: American Diabetes Association
Erscheinungsjahr
2005
Link zum Volltext
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
Effect of Dehydroepiandrosterone Replacement on Insulin Sensitivity and Lipids in Hypoadrenal Women
Ketan Dhatariya ,
Maureen L. Bigelow and
K. Sreekumaran Nair
From the Endocrine Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota
Address correspondence and reprint requests to K. Sreekumaran Nair, MD, PhD, Endocrine Research Unit, Joseph 5-194, Mayo Clinic
and Foundation, 200 First St., SW, Rochester, MN 55905. E-mail: nair{at}mayo.edu .
Abstract
DHEA (dehydroepiandrosterone) replacement is not part of the current standard of care in hypoadrenal subjects. Animal studies
have shown that DHEA administration prevents diabetes. To determine the physiological effect of DHEA replacement on insulin
sensitivity in adrenal-deficient women, we performed a single-center, randomized, double-blind, placebo-controlled, crossover
study in 28 hypoadrenal women (mean age 50.2 ± 2.87 years) who received a single 50-mg dose of DHEA daily or placebo. After
12 weeks, insulin sensitivity was assessed using a hyperinsulinemic-euglycemic clamp. DHEA replacement significantly increased
DHEA-S (sulfated ester of DHEA), bioavailable testosterone, and androstenedione and reduced sex hormone−binding globulin levels.
Fasting plasma insulin and glucagon were lower with DHEA (42 ± 4.94 vs. 53 ± 6.58 pmol/l [ P = 0.005] and 178 ± 11.32 vs. 195.04 ± 15 pmol/l [ P = 0.02], respectively). The average amount of glucose needed to maintain similar blood glucose levels while infusing the
same insulin dosages was higher during DHEA administration (358 ± 24.7 vs. 320 ± 24.6 mg/min; P < 0.05), whereas endogenous glucose production was similar. DHEA also reduced total cholesterol ( P < 0.005), triglycerides ( P < 0.011), LDL cholesterol ( P < 0.05), and HDL cholesterol ( P < 0.005). In conclusion, replacement therapy with 50 mg of DHEA for 12 weeks significantly increased insulin sensitivity
in hypoadrenal women, thereby suggesting that DHEA replacement could have a potential impact in preventing type 2 diabetes.
AP, alkaline phosphatase
AST, aspartate transferase
DHEA, dehydroepiandrosterone
DHEA-S, sulfated ester of DHEA
EGP, endogenous glucose production
FFM, fat-free body mass
IGFBP, IGF binding protein
IRMA, immunoradiometric assay
RIA, radioimmunoassay
SHBG, sex hormone−binding globulin
Footnotes
Accepted December 7, 2004.
Received June 10, 2004.
DIABETES